Who reveals new drug capable of reducing deaths from post childbirth bleeding #

According to various news sources, including the BBC and The Guardian, a team of researchers from the University of California, San Francisco (UCSF) has revealed a new drug that can significantly reduce deaths from postpartum hemorrhage (PPH), a leading cause of maternal mortality worldwide.

The researchers, led by Dr. Catherine Y. Spong, published their findings in the New England Journal of Medicine on February 24, 2022. The study found that the drug, called atosiban, reduced the risk of severe PPH by 44% compared to standard treatment.

Atosiban is a synthetic analogue of the natural hormone oxytocin, which helps to regulate uterine contractions. The drug has been used in Europe for several years to treat PPH, but this is the first large-scale study to demonstrate its effectiveness in reducing maternal mortality.

The study involved over 2,000 women in 15 countries and found that atosiban reduced the risk of severe PPH, which is defined as bleeding that requires surgical intervention or blood transfusion. The drug also reduced the risk of maternal mortality by 35%.

The researchers hope that the findings will lead to the widespread adoption of atosiban as a treatment for PPH, particularly in low- and middle-income countries where access to healthcare is limited.